Molecular Partners AG
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Apr 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 18, 2026The maintenance fee for Capping Modules for Designed Ankyrin Repeat Proteins (US 10,322,190) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Feb 6, 2027The maintenance fee for Binding Proteins Comprising at Least Two Repeat Domains Against HER2 (US 10,370,414) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
- 1 fee due Apr 20, 2027The maintenance fee for Designed Ankyrin Repeat Proteins Binding to Platelet-Derived Growth Factor (US 9,163,070) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
- 2 fees due Jun 5 to 29, 2027 · next Jun 5
- 2 fees due Sep 15 to 22, 2027 · next Sep 15
- 1 fee due Nov 12, 2027The maintenance fee for Modified Binding Proteins Inhibiting the VEGF-A Receptor Interaction (US 10,646,542) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,710,187 | Modified Binding Proteins Inhibiting the VEGF-A Receptor Interaction In force · High confidence | In force | High confidence | |
| US 9,289,466 | Modified Binding Proteins Inhibiting the VEGF-A Receptor Interaction In force · High confidence | In force | High confidence | |
| US 9,849,158 | Modified Binding Proteins Inhibiting the VEGF-A Receptor Interaction In force · High confidence | In force | High confidence | |
| US 10,646,542 | Modified Binding Proteins Inhibiting the VEGF-A Receptor Interaction In force · High confidence | In force | High confidence | |
| US 8,901,076 | Binding Proteins Inhibiting the VEGF-A Receptor Interaction In force · High confidence | In force | High confidence | |
| US 9,221,892 | Improved Capping Modules for Designed Ankyrin Repeat Proteins In force · High confidence | In force | High confidence | |
| US 9,284,361 | Designed Repeat Proteins Binding to Serum Albumin In force · High confidence | In force | High confidence | |
| US 9,717,802 | Improved Capping Modules for Designed Ankyrin Repeat Proteins In force · Medium confidence | In force | Medium confidence | |
| US 9,775,912 | Designed Repeat Proteins Binding to Serum Albumin In force · Low confidence | In force | Low confidence | |
| US 10,322,190 | Capping Modules for Designed Ankyrin Repeat Proteins In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 22: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending · 11 abandoned · 5 no status recorded